Item request has been placed!
×
Item request cannot be made.
×
Processing Request
The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
- Publication Information:
Original Publication: [Amsterdam] : Elsevier B.V., [2014]-
- Subject Terms:
- Abstract:
Background: In mesothelioma (MPM), clinical evidence indicates that the absolute eosinophil count negatively correlates with overall survival and response to standard chemotherapy. Since eosinophils poorly infiltrate MPM tumours, we hypothesised that endocrine rather than paracrine pathways mediate the therapeutic response. We thus studied the effect of eosinophil-associated factors on response to chemotherapy in mesothelioma.
Methods: The culture supernatant conditioned by primary human eosinophils was added to mesothelioma cells in presence of the standard chemotherapeutic regimen. The effectiveness of an anti-eosinophil treatment was evaluated in a preclinical model of C57BL/6 mice transplanted with mesothelioma tumour cells.
Findings: Supernatant of eosinophils differentiated from EOL1 cells or directly isolated from peripheral blood inhibited apoptosis induced by cisplatin and pemetrexed in 2D cultures and in spheroids. Transcriptomic analysis indicated that the anti-apoptotic effect mediated by eosinophils involved molecular interactions with the Charcot-Leyden Crystal protein or Galectin-10 (CLC-P/Gal10). The functional relevance of CLC-P/Gal10 was demonstrated by antibody-mediated depletion. Recombinant human CLC-P/Gal10 mimicked the anti-apoptotic activity of eosinophil-derived supernatants. In the mouse model, eosinophilia did not significantly affect tumour growth but altered the response to chemotherapy. Finally, pretreatment of eosinophilia with the anti-Siglec-F antibody before chemotherapy restored the effectiveness of the treatment.
Interpretation: This study provides a mechanistic rationale to clinical evidence correlating the poor outcome of patients with mesothelioma and with eosinophil-derived CLC-P/Gal10, opening new prospects for intervention in this fatal solid tumour.
Funding: Belgian Foundation against Cancer, Fonds National de la Recherche Scientifique (FNRS), Télévie, Foundation Léon Fredericq, ULiège.
Competing Interests: Declaration of interests The authors declare no conflict of interest in the scope of this work. Beyond the scope of this study, RL declares consultancy fees from GSK and AstraZeneca, and grants from GSK AstraZeneca, Sanofi and Chiesi.
(Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Contributed Indexing:
Keywords: Charcot-leyden crystal protein; Chemoresistance; Eosinophils; Mesothelioma
- Accession Number:
EC 3.1.1.5 (lysolecithin acylhydrolase)
EC 3.1.1.5 (Lysophospholipase)
Q20Q21Q62J (Cisplatin)
0 (Antineoplastic Agents)
0 (Culture Media, Conditioned)
04Q9AIZ7NO (Pemetrexed)
0 (Glycoproteins)
- Publication Date:
Date Created: 20241029 Date Completed: 20241116 Latest Revision: 20241116
- Publication Date:
20241118
- Accession Number:
PMC11550731
- Accession Number:
10.1016/j.ebiom.2024.105418
- Accession Number:
39471751
No Comments.